Go Pro

GSK (GSK) 10K Form and Latest SEC Filings 2026

GSK logo
$50.19 +2.06 (+4.27%)
As of 03:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest GSK SEC Filings & Recent Activity

GSK (NYSE:GSK) has submitted 1,667+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in GSK's financial statements. The most recent filing was a Form 6-K submitted on September 14, 2026.

20-F
GSK Files Annual Report on Mar. 6, 2026

The 20-F contains GSK's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

GSK SEC Filing History

Browse GSK's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
09/14/2026 6:24 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/14/2026 6:04 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/11/2026 9:30 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/10/2026 9:31 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/10/2026 7:53 AM
GLAXOSMITHKLINE CAPITAL INC (1224462) Filer
GSK (1131399) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
09/10/2026 5:09 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/09/2026 9:45 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/09/2026 9:31 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/09/2026 5:19 AM
GSK (1131399) Subject
Form FWP
09/08/2026 8:06 AM
GLAXOSMITHKLINE CAPITAL INC (1224462) Filer
GSK (1131399) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
09/08/2026 7:27 AM
GLAXOSMITHKLINE CAPITAL INC (1224462) Filer
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/01/2026 11:26 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/01/2026 6:46 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/26/2026 9:37 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/24/2026 9:35 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/24/2026 5:57 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/24/2026 5:20 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/20/2026 10:19 AM
GSK (1131399) Subject
Martinez Maria E (1761768) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/18/2026 9:34 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/13/2026 3:32 PM
GSK (1131399) Filer
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
08/13/2026 10:33 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/11/2026 10:03 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/03/2026 10:16 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/30/2026 11:25 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/22/2026 11:52 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/20/2026 9:13 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/17/2026 6:14 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/17/2026 5:50 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/16/2026 9:45 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/15/2026 8:11 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/15/2026 8:00 AM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-T/A
07/14/2026 10:20 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/13/2026 10:28 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/13/2026 5:29 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/10/2026 7:44 AM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-T/A
07/10/2026 7:13 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/09/2026 10:27 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/09/2026 6:27 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/07/2026 3:44 PM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-T/A
07/01/2026 9:02 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/29/2026 9:25 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Gold Miners Post Record Cash Flow Even as Prices Pull Back (Ad)

The four largest gold miners are generating record free cash flow, even with gold pulling back from recent highs. Margins as high as 75 percent make this the most profitable stretch in their history. Yet junior gold miners, the prime buyout targets for these cash-rich majors, are still priced as if gold were stuck at 1800 dollars an ounce instead of today's levels. Analyst Garrett Goggin calls this the Golden Anomaly, a gap he says rarely lasts long once a gold bull market gets going.tc pixel

See the junior gold miners poised for a major buyout wave
06/29/2026 9:20 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/26/2026 9:02 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/24/2026 3:03 PM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-T/A
06/24/2026 9:39 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/24/2026 9:46 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/24/2026 6:15 AM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-T
06/23/2026 10:05 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/22/2026 10:00 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/17/2026 11:20 AM
GSK (1131399) Filer
Form 11-K
Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d)  
06/17/2026 11:02 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/17/2026 11:04 AM
GSK (1131399) Filer
Form 11-K
Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d)  
06/15/2026 9:02 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/12/2026 5:32 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/11/2026 9:42 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/10/2026 3:54 PM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-C
06/10/2026 9:36 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/09/2026 4:20 PM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-C
06/09/2026 12:37 PM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/09/2026 6:13 AM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-C
06/09/2026 5:18 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2026 9:46 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2026 9:00 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/28/2026 5:02 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/27/2026 9:34 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/26/2026 9:23 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/26/2026 9:17 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/22/2026 6:19 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/20/2026 9:39 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/20/2026 9:40 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/19/2026 10:01 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/18/2026 10:03 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/18/2026 5:29 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/14/2026 3:45 PM
GSK (1131399) Filer
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
05/14/2026 11:22 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/11/2026 9:59 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/11/2026 5:42 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/11/2026 5:31 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2026 12:52 PM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2026 10:18 AM
FMR LLC (315066) Filed by
GSK (1131399) Subject
Form SCHEDULE 13G
05/05/2026 11:54 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/01/2026 10:08 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/01/2026 10:11 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2026 11:00 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2026 7:09 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2026 10:18 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2026 6:24 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/27/2026 7:13 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/27/2026 5:58 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/24/2026 10:20 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2026 5:03 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Why major institutions are piling into this digital asset now (Ad)

BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel

Get the name, the ticker, and exactly how to buy it
04/22/2026 5:06 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/21/2026 5:03 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/20/2026 11:46 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/20/2026 5:37 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/20/2026 5:19 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/17/2026 5:16 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2026 12:01 PM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2026 5:42 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2026 5:39 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

GSK SEC Filings - Frequently Asked Questions

GSK (GSK) has submitted 1,667+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

GSK's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on GSK's financial statements page.

The most recent filing was a Form 6-K submitted on September 14, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NYSE:GSK are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 9/14/2026. New filings are added as they're published.
From Our Partners